Lv1
20 积分 2024-05-28 加入
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors
1天前
待确认
P1.12A.07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation
23天前
已关闭
3O IGSF8 is an innate immune checkpoint and cancer immunotherapy target
25天前
已完结
3O IGSF8 is an innate immune checkpoint and cancer immunotherapy target
25天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
28天前
已完结
https://actaodontologicalat.com/wp-content/uploads/2022/05/aol_2022_35-1-03.pdf
1个月前
已关闭
Abstract 583: AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage
1个月前
已完结
BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
1个月前
已完结
A new radioactive microsphere: Y-90 carbon microsphere for selective internal radiation therapy of advanced liver cancer
1个月前
已完结
177Lu-LNC1004 Radioligand Therapy in Patients with End-Stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study
1个月前
已关闭
皖公网安备34019202002308
